Relationship between cerebral blood flow reduction patterns on scintigraphy and nonmotor symptoms in new-onset Lewy body disease
Abstract
Background: This study aimed to investigate the relationship between patterns of reduced cerebral blood flow (CBF) evaluated by means of 123I-N-isopropyl-p-iodoamphetamine ([123I]IMP) scintigraphy and nonmotor symptoms in new-onset Lewy body disease (Parkinson’s disease and dementia with Lewy bodies [DLB]). Material and methods: Twenty-four patients diagnosed with new-onset Parkinson’s disease or DLB underwent [123I]IMP CBF scintigraphy at St. Marianna Medical University Hospital between January 1, 2010, and March 30, 2018. The reductions in CBF in various brain regions were analyzed using the three-dimensional stereotactic surface projection method and were compared to standard database values, yielding extent values (%). The extent values were evaluated in relation to the presence/absence of motor or nonmotor symptoms such as visual hallucinations, auditory hallucinations, delirium, depression, delusions, and dementia. Results: The extent value was 100% in the angular, supramarginal, and lingual gyri; 95% in the orbital gyri; and 92.6% in the fusiform gyri. The extent value in patients without hallucinations and those with visual hallucinations was 41.2% and 54.3%, respectively, in the frontal lobe (p = 0.02) and 33.3% and 51.0%, respectively, in the medial prefrontal gyri (p = 0.02). Age-adjusted multivariate analysis showed that extent values in the frontal lobe were associated with visual hallucinations (odds ratio: 1.09, 95% confidence interval 1.00–1.18, p = 0.04). Conclusions: The above results show that the CBF is reduced in several areas of the cerebral cortex and suggest an association between reduced blood flow in the frontal lobe and the appearance of visual hallucinations in patients with new-onset DLB.
Keywords: hallucinationsdementia with Lewy bodiesradionuclide imaging
References
- Dias JA, Felgueiras MM, Sanchez JP, et al. The prevalence of Parkinson's disease in Portugal. A population approach. Eur J Epidemiol. 1994; 10(6): 763–767.
- Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010; 67(6): 715–725.
- Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017; 32(9): 1264–1310.
- Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001; 70(6): 727–733.
- Iaccarino L, Sala A, Caminiti SP, et al. The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. Cortex. 2018; 108: 13–24.
- Imabayashi E, Soma T, Sone D, et al. Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer's disease using brain perfusion SPECT. Ann Nucl Med. 2017; 31(7): 536–543.
- Imon Y, Matsuda H, Ogawa M, et al. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med. 1999; 40(10): 1583–1589.
- Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett. 1997; 235(1-2): 49–52.
- Imabayashi E, Yokoyama K, Tsukamoto T, et al. The cingulate island sign within early Alzheimer's disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies. EJNMMI Res. 2016; 6(1): 67.
- Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995; 36(7): 1238–1248.
- Yamazaki T, Inui Y, Ichihara T, et al. Clinical utility of the normal database of I-iodoamphetamine brain perfusion single photon emission computed tomography for statistical analysis using computed tomography-based attenuation correction: a multicenter study. Ann Nucl Med. 2019; 33(11): 835–841.
- Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med. 1997; 38(5): 797–802.
- Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6): 745–752.
- McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12): 1863–1872.
- Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB. ed. Recent Developments in Parkinson’s Disease, Vol 2. Macmillan Healthcare Information, Florham Park, NJ 1987: 153–163.
- Fällmar D, Lilja J, Danfors T, et al. Z-score maps from low-dose F-FDG PET of the brain in neurodegenerative dementia. Am J Nucl Med Mol Imaging. 2018; 8(4): 239–246.
- Pasquier J, Michel B, Brenot-Rossi I, et al. Value of 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002; 29(10): 1342–1348.
- Ishii K, Yamaji S, Kitagaki H, et al. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999; 53(2): 413–416.
- Shimizu S, Hanyu H, Hirao K, et al. Deep gray matter hyperperfusion with occipital hypoperfusion in dementia with Lewy bodies. Eur J Neurol. 2007; 14(11): 1299–1301.
- Kikuchi A, Takeda A, Kimpara T, et al. Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci. 2001; 193(1): 29–36.
- Kawasaki Y, Ohtaki J, Toba K, et al. Relationship of Alzheimer disease severity and 99mTc-ECD SPECT brain blood-flow imaging (in Japanese). J Kyorin Med Soc. 2007; 38: 21–28.
- Livingston KE, Escobar A. Anatomical bias of the limbic system concept. A proposed reorientation. Arch Neurol. 1971; 24(1): 17–21.
- Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002; 125(Pt 2): 391–403.
- Gallagher DA, Parkkinen L, O'Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain. 2011; 134(Pt 11): 3299–3309.
- Nagahama Y, Okina T, Suzuki N, et al. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 2010; 133(Pt 2): 557–567.
- Ishii K, Ito K, Nakanishi A, et al. Computer-assisted system for diagnosing degenerative dementia using cerebral blood flow SPECT and 3D-SSP: a multicenter study. Jpn J Radiol. 2014; 32(7): 383–390.
- Kirino E. Three-dimensional stereotactic surface projection in the statistical analysis of single photon emission computed tomography data for distinguishing between Alzheimer's disease and depression. World J Psychiatry. 2017; 7(2): 121–127.
- Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999; 56(5): 595–601.
- Coelho M, Marti MJ, Tolosa E, et al. Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol. 2010; 257(9): 1524–1532.
- Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23(6): 837–844.
- Matar E, Ehgoetz Martens KA, Halliday GM, et al. Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. J Neurol. 2020; 267(2): 380–389.
- Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013; 70(11): 1396–1402.
- Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med. 2019; 49(14): 2342–2353.
- Szeto JYy, O'Callaghan C, Shine JM, et al. The relationships between mild cognitive impairment and phenotype in Parkinson's disease. NPJ Parkinsons Dis. 2015; 1: 15015.
